Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
← catalyst calendarSponsored by Reviva Pharmaceuticals (industry) · RVPH — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
690estimated
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-01-24 | actual | When the study began enrolling |
| Primary completion | Feb 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-12-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Interventions
- Drug: Brilaroxazine — also filed as RP5063
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFDouble Blind Safety and Efficacy of Brilaroxazine (RP5063)
measured 28 days
Open label Safety and Efficacy of Brilaroxazine (RP5063)
measured 52 weeks
Permalink · RVPH's whole pipeline · Catalyst calendar · Every registered study · What changed